Segment Disclosure (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Summary of Net Loss Related To Segment Expenses

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Collaboration revenue	$	—		$	—		$	7,500		$	—
Less:
Direct external research and development costs
Azetukalner		43,405			23,344			74,906			46,557
Pre-clinical, discovery and other programs		6,111			6,169			11,078			9,830
Personnel-related expenses		22,386			16,053			45,026			30,907
Stock-based compensation expense		13,713			14,716			25,887			24,116
Other research and development costs		2,600			3,163			6,025			6,177
Other general and administrative costs		6,014			5,659			11,545			10,558
Interest income		(7,199	)		(10,837	)		(15,282	)		(22,192	)
Other segment items(1)		(2,324	)		(343	)		(1,932	)		(98	)
Net loss	$	(84,706	)	$	(57,924	)	$	(149,753	)	$	(105,855	)

(1)Other segment items include foreign exchange gain and income tax (recovery) expense.